EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of PRDX5 as A Target for The Treatment of Castration‐Resistant Prostate Cancer

Rong Wang, Yuanyuan Mi, Jiang Ni, Yang Wang, Lingwen Ding, Xuebin Ran, Qiaoyang Sun, Soo Yong Tan, H Phillip Koeffler, Ninghan Feng, Yong Q Chen iD

Advanced Science · 2024-03 · 11 (9)

DOI: 10.1002/advs.202304939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.12.2023. Verfasst von Rong Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiangnan University Medical Center, Jiangnan University, Wuxi, 214002, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Medical Research Council, Jiangsu Provincial Key Research and Development Program, Major Research Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment of castration‐resistant prostate cancer (CRPC) is a long‐standing clinical challenge. Traditionally, CRPC drugs work by either reducing dihydrotestosterone biosynthesis or blocking androgen receptor (AR) signaling. Here it is demonstrated that AR inhibitor treatment gives rise to a drug‐tolerant persister (DTP) state. The thioredoxin/peroxiredoxin pathway is up‐regulated in DTP cells. Peroxiredoxin 5 (PRDX5) promotes AR inhibitor resistance and CRPC development. Inhibition of PRDX5 suppresses DTP cell proliferation in culture, dampens CRPC development in animal models, and stabilizes PSA progression and metastatic lesions in patients. Therefore, the study provides a novel mechanism and potential target for the management of castration‐resistant prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleAnimalsHumansReceptors, AndrogenPeroxiredoxinsSignal Transduction

Stichwörter der Autor:innen

castration-resistant prostate cancerdrug-tolerant persisterperoxiredoxin 5polaprezincstachyose

Substanzen

Receptors, AndrogenPeroxiredoxinsPRDX5 protein, human

Autor:innen und Institutionen

  • Jiangnan University Medical Center, Jiangnan University, Wuxi, 214002, China.
  • Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
  • Affiliated Hospital, Jiangnan University, Wuxi, 214122, China.
  • Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore.
  • Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
  • Department of Hematology, Singapore General Hospital, Singapore, 169608, Singapore.

ORCID-Profile: Yong Q Chen

Förderung

  • National Medical Research Council
  • Jiangsu Provincial Key Research and Development Program
  • Major Research Plan

Zitieren

APA

Wang, R., Mi, Y., Ni, J., Wang, Y., Ding, L., Ran, X., Sun, Q., Tan, S. Y., Koeffler, H. P., Feng, N., & Chen, Y. Q. (2024). Identification of PRDX5 as A Target for The Treatment of Castration‐Resistant Prostate Cancer. Advanced Science, 11(9). https://doi.org/10.1002/advs.202304939

Vancouver

Wang R, Mi Y, Ni J, Wang Y, Ding L, Ran X, et al. Identification of PRDX5 as A Target for The Treatment of Castration‐Resistant Prostate Cancer. Advanced Science. 2024;11(9). doi:10.1002/advs.202304939

BibTeX
@article{Wang2024,
  author = {Wang, Rong and Mi, Yuanyuan and Ni, Jiang and Wang, Yang and Ding, Lingwen and Ran, Xuebin and Sun, Qiaoyang and Tan, Soo Yong and Koeffler, H Phillip and Feng, Ninghan and Chen, Yong Q},
  title = {Identification of PRDX5 as A Target for The Treatment of Castration‐Resistant Prostate Cancer},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {9},
  doi = {10.1002/advs.202304939}
}
Kostenlos starten →